Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.56 +1.7%	$2.74	$0.80 ▼ $4.08	$934.98M	0.85	3.21 million shs	3.60 million shs
AVDL Avadel Pharmaceuticals	$9.32 -0.5%	$8.99	$6.38 ▼ $17.30	$901.61M	1.45	1.27 million shs	1.27 million shs
NBTX Nanobiotix	$4.38 -4.8%	$3.87	$2.76 ▼ $6.00	$202.20M	0.36	15,789 shs	4,082 shs
NTLA Intellia Therapeutics	$9.60 +0.2%	$8.24	$5.90 ▼ $28.18	$994.39M	2.14	2.88 million shs	5.76 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	0.00%	-2.47%	+21.92%	+67.14%	+252.48%
AVDL Avadel Pharmaceuticals	0.00%	-0.21%	-0.53%	+8.75%	-40.26%
NBTX Nanobiotix	0.00%	-23.96%	+12.31%	+20.99%	-3.52%
NTLA Intellia Therapeutics	0.00%	+14.97%	-0.72%	+6.67%	-61.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.0864 of 5 stars	3.6	2.0	4.0	3.4	0.8	0.6
AVDL Avadel Pharmaceuticals	2.2191 of 5 stars	3.5	1.0	0.0	2.6	1.7	0.6
NBTX Nanobiotix	2.9538 of 5 stars	3.3	5.0	0.0	3.6	0.0	0.6
NTLA Intellia Therapeutics	4.4462 of 5 stars	4.3	1.0	4.7	2.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	89.61% Upside
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	94.92% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	82.65% Upside
NTLA Intellia Therapeutics	2.67	Moderate Buy	$34.95	264.06% Upside

Current Analyst Ratings Breakdown

Latest NBTX, AKBA, NTLA, and AVDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/12/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $45.00
5/9/2025	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $10.00
5/9/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$68.00 ➝ $68.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.84	N/A	N/A	($0.23) per share	-15.48
AVDL Avadel Pharmaceuticals	$169.12M	5.33	N/A	N/A	$0.77 per share	12.10
NBTX Nanobiotix	$39.18M	5.27	N/A	N/A	($1.51) per share	-2.90
NTLA Intellia Therapeutics	$57.88M	17.18	N/A	N/A	$8.56 per share	1.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	155.33	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)

Latest NBTX, AKBA, NTLA, and AVDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
NBTX Nanobiotix	N/A	1.04	1.04
NTLA Intellia Therapeutics	N/A	4.90	4.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AVDL Avadel Pharmaceuticals	69.19%
NBTX Nanobiotix	38.81%
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
AVDL Avadel Pharmaceuticals	4.80%
NBTX Nanobiotix	3.45%
NTLA Intellia Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	92.10 million	Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable

NBTX, AKBA, NTLA, and AVDL Headlines

Recent News About These Companies

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

June 19 at 1:10 AM | finance.yahoo.com

Wedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)

June 18 at 6:38 AM | theglobeandmail.com

Intellia Therapeutics (NASDAQ:NTLA) Earns Neutral Rating from Wedbush

June 18 at 2:23 AM | americanbankingnews.com

HC Wainwright Reaffirms Buy Rating for Intellia Therapeutics (NASDAQ:NTLA)

June 18 at 1:23 AM | americanbankingnews.com

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

June 17 at 3:36 PM | msn.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Here's Why

June 17 at 12:16 PM | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Receives Neutral Rating from Wedbush

June 16, 2025 | marketbeat.com

6NTLA : Assessing Intellia Therapeutics: Insights From 9 Financial...

June 16, 2025 | benzinga.com

Intellia Therapeutics' (NTLA) Buy Rating Reaffirmed at HC Wainwright

June 16, 2025 | marketbeat.com

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

June 15, 2025 | globenewswire.com

Cantor Fitzgerald Estimates NTLA FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Brokers Issue Forecasts for NTLA FY2026 Earnings

June 10, 2025 | marketbeat.com

Intellia Therapeutics Inc.

June 9, 2025 | barrons.com

Intellia Therapeutics (NASDAQ:NTLA) Trading Up 8.7% - Should You Buy?

June 6, 2025 | marketbeat.com

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 5, 2025 | globenewswire.com

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

June 4, 2025 | zacks.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Wellington Management Group LLP

June 4, 2025 | marketbeat.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from Analysts

June 4, 2025 | marketbeat.com

Canaccord Genuity Group Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

June 3, 2025 | marketbeat.com

Nuveen Asset Management LLC Decreases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

June 3, 2025 | marketbeat.com

Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

June 1, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX, AKBA, NTLA, and AVDL Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.56 +0.06 (+1.71%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.53 -0.03 (-0.84%)

As of 06/18/2025 07:58 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Avadel Pharmaceuticals NASDAQ:AVDL

$9.32 -0.05 (-0.53%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.32 0.00 (0.00%)

As of 06/18/2025 04:33 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Nanobiotix NASDAQ:NBTX

$4.38 -0.22 (-4.78%)

Closing price 06/18/2025 03:03 PM Eastern

Extended Trading

$4.49 +0.11 (+2.40%)

As of 06/18/2025 05:45 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Intellia Therapeutics NASDAQ:NTLA

$9.60 +0.02 (+0.21%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.30 -0.31 (-3.18%)

As of 06/18/2025 07:59 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time